Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.27% on an annualized basis producing an average annual return of 21.11%. Currently, Regeneron Pharmaceuticals has a market capitalization of $73.81 billion.
Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $4,539.94 today based on a price of $704.00 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1777678266_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="comp_fig" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1777678266_0.png"/>

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

SBIO

Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered an average annual return of 21.11% over the past 20 years, outperforming the market by 12.27%. With a current market capitalization of $73.81 billion, a $100 investment in REGN stock two decades ago would now be worth $4,539.94, highlighting the significant impact of compounded returns on investment growth.

benzinga_article

Regeneron Pharma

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years